CL2008000936A1 - Derivados de piridina y pirimidina, antagonistas del mglur2; composicion farmaceutica que los contiene; procedimiento de preparacion; y su uso en el tratamiento y profilaxis de trastornos neurologigos agudos y/o cronicos, tales como psicosis, esquizo - Google Patents

Derivados de piridina y pirimidina, antagonistas del mglur2; composicion farmaceutica que los contiene; procedimiento de preparacion; y su uso en el tratamiento y profilaxis de trastornos neurologigos agudos y/o cronicos, tales como psicosis, esquizo

Info

Publication number: CL2008000936A1
Authority: CL; Chile
Prior art keywords: pirimidina; piridina; mglur2; skiing; psychosis
Prior art date: 2007-04-02

Application number

CL200800936A

Other languages

English (en)

Inventor

Gatti Mcarthur Juergen Silvia

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-02

Filing date

2008-04-01

Publication date

2008-10-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39457413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000936(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-04-01 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2008-10-03 Publication of CL2008000936A1 publication Critical patent/CL2008000936A1/es

Links

101150016175 Grm2 gene Proteins 0.000 title 1
102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title 1
208000012902 Nervous system disease Diseases 0.000 title 1
208000025966 Neurological disease Diseases 0.000 title 1
208000028017 Psychotic disease Diseases 0.000 title 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
230000001154 acute effect Effects 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
230000001684 chronic effect Effects 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
238000011321 prophylaxis Methods 0.000 title 1
238000011282 treatment Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Otolaryngology (AREA)
Anesthesiology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

CL200800936A 2007-04-02 2008-04-01 Derivados de piridina y pirimidina, antagonistas del mglur2; composicion farmaceutica que los contiene; procedimiento de preparacion; y su uso en el tratamiento y profilaxis de trastornos neurologigos agudos y/o cronicos, tales como psicosis, esquizo CL2008000936A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP07105429		2007-04-02

Publications (1)

Publication Number	Publication Date
CL2008000936A1 true CL2008000936A1 (es)	2008-10-03

Family

ID=39457413

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200800936A CL2008000936A1 (es)	2007-04-02	2008-04-01	Derivados de piridina y pirimidina, antagonistas del mglur2; composicion farmaceutica que los contiene; procedimiento de preparacion; y su uso en el tratamiento y profilaxis de trastornos neurologigos agudos y/o cronicos, tales como psicosis, esquizo

Country Status (17)

Country	Link
US (2)	US8012986B2 (es)
EP (1)	EP2142527B1 (es)
JP (1)	JP5303544B2 (es)
KR (1)	KR101143152B1 (es)
CN (1)	CN101641346B (es)
AR (1)	AR065891A1 (es)
AT (1)	ATE493400T1 (es)
AU (1)	AU2008233956B2 (es)
BR (1)	BRPI0809971A2 (es)
CA (1)	CA2681733A1 (es)
CL (1)	CL2008000936A1 (es)
DE (1)	DE602008004236D1 (es)
IL (1)	IL200780A (es)
MX (1)	MX2009010505A (es)
PE (1)	PE20090103A1 (es)
TW (1)	TW200845999A (es)
WO (1)	WO2008119689A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2231642B1 (en) *	2008-01-11	2013-10-23	Novartis AG	Pyrimidines as kinase inhibitors
WO2012020820A1 (ja)	2010-08-11	2012-02-16	大正製薬株式会社	ヘテロアリール－ピラゾール誘導体
JP2014062047A (ja) *	2011-01-21	2014-04-10	Taisho Pharmaceutical Co Ltd	ピラゾール誘導体
CA2849189A1 (en) *	2011-09-21	2013-03-28	Cellzome Limited	Morpholino substituted urea or carbamate derivatives as mtor inhibitors
AU2013216935C1 (en) *	2012-02-08	2017-12-14	John Emmerson Campbell	Heteroaryl compounds and methods of use thereof
KR20150070187A (ko)	2012-10-23	2015-06-24	에프. 호프만-라 로슈 아게	자폐 장애의 치료를 위한 ｍｇｌｕ２／３ 길항제
EP3134089A2 (en)	2014-04-23	2017-03-01	F. Hoffmann-La Roche AG	Mglu2/3 antagonists for the treatment of intellectual disabilities
JP6552061B2 (ja) *	2014-06-10	2019-07-31	サンフォード−バーンハムメディカルリサーチインスティテュート	代謝型グルタミン酸受容体の負のアロステリックモジュレーター（ｎａｍｓ）とその使用
EA201990400A1 (ru)	2016-07-29	2019-07-31	Суновион Фармасьютикалз, Инк.	Соединения и композиции и их применение
MX2019000982A (es)	2016-07-29	2019-07-04	Sunovion Pharmaceuticals Inc	Compuestos y composiciones y usos de los mismos.
JP7191085B2 (ja)	2017-08-02	2022-12-16	サノビオンファーマシューティカルズインク	イソクロマン化合物およびその使用
MX2020013827A (es) *	2018-06-22	2021-03-25	Bayer Ag	Proceso de preparacion de compuestos triciclicos.
CN113784755B (zh)	2019-03-14	2024-05-10	赛诺维信制药公司	异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2438991C (en)	2001-02-21	2010-08-17	Nps Pharmaceuticals, Inc.	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CA2520870A1 (en)	2003-04-03	2004-10-21	Merck & Co., Inc.	Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2004227854B2 (en) *	2003-04-04	2009-07-23	Merck & Co., Inc.	Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
EP1683804B1 (en) *	2003-11-04	2013-07-31	Takasago International Corporation	Platinum complex and luminescent element
US20060173048A1 (en)	2005-02-03	2006-08-03	Mcarthur Silvia G	Imidazole derivatives
JP5249919B2 (ja)	2006-03-29	2013-07-31	エフ．ホフマン−ラロシュアーゲー	ｍＧｌｕＲ２アンタゴニストとしてのピリジン及びピリミジン誘導体
US20070236568A1 (en)	2006-04-11	2007-10-11	Metke Anthony R	Method and system for communicating incident scene information

2008
- 2008-03-24 US US12/053,648 patent/US8012986B2/en not_active Expired - Fee Related
- 2008-03-25 AT AT08718155T patent/ATE493400T1/de active
- 2008-03-25 CN CN2008800096420A patent/CN101641346B/zh not_active Expired - Fee Related
- 2008-03-25 AU AU2008233956A patent/AU2008233956B2/en not_active Ceased
- 2008-03-25 JP JP2010501476A patent/JP5303544B2/ja not_active Expired - Fee Related
- 2008-03-25 BR BRPI0809971-5A2A patent/BRPI0809971A2/pt not_active IP Right Cessation
- 2008-03-25 KR KR1020097020481A patent/KR101143152B1/ko not_active Expired - Fee Related
- 2008-03-25 CA CA002681733A patent/CA2681733A1/en not_active Abandoned
- 2008-03-25 MX MX2009010505A patent/MX2009010505A/es active IP Right Grant
- 2008-03-25 DE DE602008004236T patent/DE602008004236D1/de active Active
- 2008-03-25 WO PCT/EP2008/053460 patent/WO2008119689A1/en not_active Ceased
- 2008-03-25 EP EP08718155A patent/EP2142527B1/en not_active Not-in-force
- 2008-03-31 TW TW097111725A patent/TW200845999A/zh unknown
- 2008-03-31 AR ARP080101333A patent/AR065891A1/es unknown
- 2008-04-01 PE PE2008000591A patent/PE20090103A1/es not_active Application Discontinuation
- 2008-04-01 CL CL200800936A patent/CL2008000936A1/es unknown
2009
- 2009-09-07 IL IL200780A patent/IL200780A/en not_active IP Right Cessation
2011
- 2011-07-08 US US13/178,531 patent/US8415380B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL200780A0 (en)	2010-05-17
WO2008119689A1 (en)	2008-10-09
US20080280924A1 (en)	2008-11-13
JP2010524852A (ja)	2010-07-22
EP2142527B1 (en)	2010-12-29
IL200780A (en)	2013-01-31
US8012986B2 (en)	2011-09-06
CN101641346A (zh)	2010-02-03
US20110263615A1 (en)	2011-10-27
CN101641346B (zh)	2013-11-06
ATE493400T1 (de)	2011-01-15
PE20090103A1 (es)	2009-02-13
MX2009010505A (es)	2009-10-19
US8415380B2 (en)	2013-04-09
BRPI0809971A2 (pt)	2014-10-07
CA2681733A1 (en)	2008-10-09
AR065891A1 (es)	2009-07-08
TW200845999A (en)	2008-12-01
AU2008233956A1 (en)	2008-10-09
EP2142527A1 (en)	2010-01-13
KR101143152B1 (ko)	2012-05-08
KR20090117902A (ko)	2009-11-13
DE602008004236D1 (de)	2011-02-10
JP5303544B2 (ja)	2013-10-02
AU2008233956B2 (en)	2013-05-02

Similar Documents

Publication	Publication Date	Title
CL2014000801A1 (es)	2014-09-12	Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos.
CL2013001093A1 (es)	2013-09-27	Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
UY31619A1 (es)	2009-08-31	Compuestos espiro como antagonistas del receptor npy y5
CL2008001632A1 (es)	2009-10-16	Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
CL2013001338A1 (es)	2014-03-28	Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
DOP2015000246A (es)	2015-11-15	Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2013003472A1 (es)	2014-08-18	Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras.
CL2014001664A1 (es)	2014-10-03	Compuestos derivados de 2-([1,4]dioxan-2-ilmetoxi)-6,7-dihidropirimido[6,1-a]isoquinolin-4-ona, antagonistas del receptor gpr84; composicion farmaceutica; metodo de tratamiento o profilaxis; y uso en el tratamiento o profilaxis de afecciones inflamatorias tales como artritis reumatoide, vasculitis, asma y psoriasis, entre otras.
CL2012003643A1 (es)	2013-08-02	Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.
CL2008000307A1 (es)	2008-05-30	Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
CL2014001752A1 (es)	2014-10-10	Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
CL2013002177A1 (es)	2013-11-29	Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
SMT201500097B (it)	2015-07-09	Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a
CL2013002053A1 (es)	2013-11-29	Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
CL2014001858A1 (es)	2014-09-26	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CL2011002056A1 (es)	2012-04-09	Compuestos derivados del acido {7-([1,2,3]triazol-1-il)-6,7,8,9-tetrahidropirido[1,2-a]indol-10-il}-acetico, antagonista del receptor crth2; composicion farmaceutica que lo comprende; utiles ene l tratamiento del asma, alergias, cancer entre otras.
CL2012001745A1 (es)	2014-07-18	Compuestos derivados de pirrolidinonas heteroaromáticas fusionadas con actividad inhibitoria de tirosina quinasa esplénica; composición farmacéutica que los comprende; uso en el tratamiento de la rinitis alérgica, asma, dermatitis atópica, lupus eritematoso sistémico, artritis reumatoide, psoriasis, epoc, entre otras
CO6440531A2 (es)	2012-05-15	2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
SV2010003642A (es)	2011-02-07	Compuestos
CL2013001754A1 (es)	2013-11-29	Compuestos derivados de enonas triciclicas y tetraciclicas de pirazolilo y pirimidinilo; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias.
CL2008001025A1 (es)	2008-10-17	Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
CL2015001483A1 (es)	2015-10-23	Compuestos derivados de hidroxiquinolina y otros heterociclos nitrogenados, antagonistas de los receptores muscarínicos y agonistas del receptor beta2 adrenérgico; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento o prevencion del asma, bronquitis cronica o epoc.
CL2007002207A1 (es)	2008-02-01	Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CL2014002557A1 (es)	2014-12-19	Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.